Methods | We examined all trial protocols and Integrated Research Application System (IRAS) forms approved by 19 research ethics committees (RECs) from the Bristol Regional Office in the United Kingdom in 2012 to allow time for trial completion and dissemination. The primary purpose of regional offices is centralized administration of the approval and monitoring of phase 1 trials. Of 5 regional offices overseeing 80 RECs, the Bristol office processes approximately 20% of approved applications. Minor differences in case mix exist between offices; Bristol was studied because it provided a good mix of trials. Application to a regional office is primarily determined by the location of the main investigation site. In the IRAS form, investigators answer questions about their trial design and methodology. We identified phase 1 trials from study objectives or details in the protocol or form.
Two investigators (A.O. and B.C.) independently extracted general characteristics and dissemination plans (eg, scientific journal) from protocols and IRAS forms. For first-inhuman trials, we extracted details about starting-dose estimation and sentinel dosing (when a participant is given the intervention ahead of others and monitored for a justified period based on the drug's pharmacology). These 2 items were the focus of recommendations by expert scientific groups after serious adverse events (SAEs) in the TGN1412 antibody firstin-human trial. 3 Trial registry information was obtained from the IRAS form or by searching registries. Study completion was ascertained from notifications to RECs; for 3 trials, registries or publications were also consulted. For completed studies, we reviewed correspondence between RECs and investigators about SAEs. 4 We confirmed
SAEs by reviewing end-of-study reports, which are comparable with synopses of clinical study reports and mandatory within 1 year of study completion. We searched PubMed, EMBASE, trial registries, sponsor websites, and Google (November 2016) for dissemination of completed studies.
Results | Among 914 ethics applications, we identified 55 phase 1 trials sponsored by UK and non-UK institutions ( Table 1) . Seventeen applications (31%) were first-in-human trials and 17 applications (31%) were oncology studies. Among firstin-human trials, strategies for estimating and administering starting doses varied, including the minimum anticipated biological effect level or pharmacologically active dose (n = 3), no observed adverse effect level (n = 3), or derived from prior studies (n = 3). Thirteen used sentinel dosing and the median duration of time between dosing of the first participant and subsequent participants was 2 days (interquartile range, 1-7). One trial justified the observation period between first and subsequent participants and 9 trials (69%) planned sentinel dosing for all cohorts in ascending dose studies (Table 1) . Thirty-nine of 55 trials were completed or discontinued (Table 2) , of which 26 provided end-of-study reports to the REC and 13 did not (median time overdue, 1.8 years [interquartile range, 0.6-2.6 years]). Six SAEs occurred in the 26 studies with end-of-study reports (935 participants) and were potentially related to the investigational agent. Two SAEs occurred in separate first-in-human trials of healthy participants: asymptomatic atrial fibrillation resolving with drug discontinuation; and rhabdomyolysis, initially judged related to the intervention but subsequently overturned. Four participants experienced SAEs in 1 oncology trial: neutropenia and enterocolitis causing death; dehydration and pancreatitis; decreased neutrophils, nausea, and vomiting; and neutropenia.
All trials were registered but 16 entries (29%) were not publicly accessible (Table 2) . 5 Seventeen of 39 completed or discontinued trials (44%) were disseminated. The trial with the rhabdomyolysis SAE was disseminated as a conference abstract but did not mention the SAE. The remaining 2 trials with SAEs were not disseminated after a median 2.8 years (interquartile range, 2.3-3.3 years).
Discussion | In this assessment of phase 1 trials by sponsors in multiple jurisdictions, details about sentinel dosing were not mentioned in protocols. Sentinel dosing limits the number of trial participants that may be affected by SAEs. Although the absence of information on sentinel dosing does not mean it was overlooked, it warrants explicit mention in protocols. Furthermore, 44% of trials in this study disseminated their results, more than a previous study in which 26 of 127 phase 1 trials (20%) disseminated results. 6 The few SAEs in this study were subject to selective reporting or nonpublication. Centralized monitoring of SAEs in phase 1 trials may be beneficial. The study is limited to a small number of trial protocols from 1 regional office, although it is likely to be representative of the United Kingdom.
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Dissemination Strategies
Intended for submission to regulatory authority 51 ( Abbreviation: IQR, interquartile range. a European Union legislation does not require that trial registry entries for phase 1 trials be publicly visible. Therefore, when the trial registration number provided in the ethics application is entered into the European Union clinical trials register, there are no records retrieved and the user is told that the trial cannot be found. When this occurred, we identified the study as "registered without a publicly accessible registry." b Alternate dissemination method if not planned for journal publication; studies may be counted more than once for this item. c Discontinued due to lack of efficacy in related trial and poor recruitment.
d Abandoned due to adverse events in nonclinical study, decision by sponsor, or an unclear reason. e Completed trials with end of study reports (n = 26).
f The median time from completion of each trial to the search for dissemination of trial results in November 2016. g Studies may be counted more than once for this item.
To the Editor Dr Aaron and colleagues 1 reevaluated the diagnosis of asthma in the community and reported absence of the diagnosis in a third of the population. There are a few concerns that merit further discussion. First, the authors reported using bronchodilator reversibility measured with forced expiratory volume in the first second of expiration (FEV 1 ) to confirm the diagnosis of asthma (vs the ratio of FEV 1 to forced vital capacity below the lower limit of normal as a marker of airflow obstruction). Although reversible airflow obstruction is seen in asthma, a large proportion of patients with chronic obstructive pulmonary disease (COPD) may have significant acute bronchodilator reversibility, and some patients with chronic asthma and fixed obstruction may not demonstrate reversibility. 2 Also, reversible airflow obstruction may be a marker of the burden of respiratory symptoms alone in the absence of a diagnosis of asthma or COPD. 3 The group of participants identified with confirmed asthma in the study could have included patients with other obstructive lung diseases that were mislabeled as asthma, which would have led to an underestimation of the authors' findings. Second, more than half of the study participants who were not found to have current asthma never underwent spirometry at the time of the initial diagnostic evaluation in the community. Among those patients who did undergo spirometry, the absence of airflow limitation in 62% of participants (40 of 64 participants) did not deter the clinician from rendering
